| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 145, Issue 5 1337-1342, Copyright © 1990 by American Association of Immunologists
ARTICLES |
J Krutmann, R Kirnbauer, A Kock, T Schwarz, E Schopf, LT May, PB Sehgal and TA Luger
Department of Dermatology II, University of Vienna, Austria.
IL-6 is a multifunctional cytokine which is produced by a variety of cells. Therefore it was examined whether anti-CD3-induced T cell activation was associated with the induction of functionally relevant IL-6 in human monocyte accessory cells. Significantly increased amounts of IL-6 were detected in supernatants of anti-CD3-treated PBMC. Stimulation of FACS-sorted greater than 98% pure monocyte accessory cells, but not of highly purified T cells with anti-CD3, resulted in an increased IL-6 production. Furthermore, anti-CD3 significantly enhanced IL-6 mRNA expression in monocyte accessory cells. IL-6 production was not limited to anti-CD3, inasmuch as equivalent IL-6 stimulation could be achieved with a mouse IgG2a isotype control antibody. In contrast to solid phase-bound mouse IgG2a, the soluble form of this antibody failed to induce IL-6 secretion indicating a requirement for Fc gamma RI receptor cross-linking. Moreover, this property may be specific for the Fc gamma RI receptor inasmuch as mouse IgG1 antibodies binding to the Fc gamma RII receptor did not significantly enhance IL-6 production. The role of IL-6 being an additional signal in T cell activation was confirmed by the finding that an anti-IL-6 antiserum was able to suppress anti-CD3-induced T cell activation. These data indicate that binding of anti-CD3 to Fc gamma RI may generate an activation signal towards the monocyte accessory cell leading to the production and secretion of monocyte IL-6, which in turn augments T cell activation, and also may be relevant to a variety of antibody-mediated immune responses against viral and bacterial infections.
This article has been cited by other articles:
|
|
 |
|
  Z.-Y. Huang, D. R. Barreda, R. G. Worth, Z. K. Indik, M.-K. Kim, P. Chien, and A. D. Schreiber Differential kinase requirements in human and mouse Fc-gamma receptor phagocytosis and endocytosis J. Leukoc. Biol., December 1, 2006; 80(6): 1553 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Staffler, A. Szekeres, G. J. Schutz, M. D. Saemann, E. Prager, M. Zeyda, K. Drbal, G. J. Zlabinger, T. M. Stulnig, and H. Stockinger Selective Inhibition of T Cell Activation Via CD147 Through Novel Modulation of Lipid Rafts J. Immunol., August 15, 2003; 171(4): 1707 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Garcia-Garcia, G. Sanchez-Mejorada, and C. Rosales Phosphatidylinositol 3-kinase and ERK are required for NF-{kappa}B activation but not for phagocytosis J. Leukoc. Biol., October 1, 2001; 70(4): 649 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Refici, D. W. Metzger, B. P. Arulanandam, M. R. Lennartz, and D. J. Loegering Fc{gamma}-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-{alpha} levels Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2001; 280(4): R1037 - R1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Keler, P. M. Guyre, L. A. Vitale, K. Sundarapandiyan, J. G. J. van de Winkel, Y. M. Deo, and R. F. Graziano Targeting Weak Antigens to CD64 Elicits Potent Humoral Responses in Human CD64 Transgenic Mice J. Immunol., December 15, 2000; 165(12): 6738 - 6742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Okayama, A. S. Kirshenbaum, and D. D. Metcalfe Expression of a Functional High-Affinity IgG Receptor, Fc{gamma}RI, on Human Mast Cells: Up-Regulation by IFN-{gamma} J. Immunol., April 15, 2000; 164(8): 4332 - 4339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Edberg, A. M. F. Yee, D. S. Rakshit, D. J. Chang, J. A. Gokhale, Z. K. Indik, A. D. Schreiber, and R. P. Kimberly The Cytoplasmic Domain of Human Fcgamma RIa Alters the Functional Properties of the Fcgamma RI{middle dot}gamma -Chain Receptor Complex J. Biol. Chem., October 15, 1999; 274(42): 30328 - 30333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Min, K. L. Legge, C. Pack, and H. Zaghouani Neonatal Exposure to a Self-Peptide-Immunoglobulin Chimera Circumvents the Use of Adjuvant and Confers Resistance to Autoimmune Disease by a Novel Mechanism Involving Interleukin 4 Lymph Node Deviation and Interferon gamma -mediated Splenic Anergy J. Exp. Med., December 7, 1998; 188(11): 2007 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yoshikawa, T. Sakihama, Y. Nakajima, and K. Tasaka Fcgamma RIII-Mediated Regulation of Hematopoiesis in Murine Bone Marrow Cells by Interleukin-3 and CD95 (Fas/Apo-1) Blood, September 1, 1997; 90(5): 1911 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Gavin, J. A. Hamilton, and P. M. Hogarth Extracellular Mutations of Non-obese Diabetic Mouse Fcgamma RI Modify Surface Expression and Ligand Binding J. Biol. Chem., July 19, 1996; 271(29): 17091 - 17099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Kiener, B. M. Rankin, P. M. Davis, S. A. Yocum, G. A. Warr, and R. I. Grove Immune Complexes of LDL Induce Atherogenic Responses in Human Monocytic Cells Arterioscler. Thromb. Vasc. Biol., July 1, 1995; 15(7): 990 - 999. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
